[{"orgOrder":0,"company":"DiscGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Rebonuputemcel","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Intradiscal injection","sponsorNew":"DiscGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Not Applicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"NVD-001","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Allogeneic Osteoblastic Cells","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Bone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Bone Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bone Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"DiscGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Discogenic Progenitor Cell Therapy","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"DiscGenics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"DiscGenics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"DiscGenics \/ Not Applicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"NVD-003","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Novadip Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NVD-003","moa":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase I\/ Phase II","graph3":"Novadip Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"","sponsorNew":"Novadip Biosciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novadip Biosciences \/ Not Applicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : Rebonuputemcel is an allogeneic, injectable disc progenitor cell therapy, is under investgaten for painful lumbar degenerative disc disease.

                          Brand Name : IDCT

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          July 16, 2024

                          Lead Product(s) : Rebonuputemcel

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : NVD-003 is an autologous therapy derived from adipose stem cells, which reverses severe bone deterioration and to achieve accelerated ossification, is being investigated as a single treatment to save limbs and restore mobility​ in patients with CPT.

                          Brand Name : NVD-003

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          May 17, 2023

                          Lead Product(s) : NVD-003

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : NVD-003, an autologous tissue engineered product generated from the patients’ own adipose stem cells, was applied in nine patients with bone non-union of the lower limb who had previously undergone several surgical procedures.

                          Brand Name : NVD-003

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          December 08, 2022

                          Lead Product(s) : NVD-003

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : High dose IDCT (Allogeneic Discogenic Progenitor Cell Therapy) also produced clinically meaningful, statistically significant improvements in function and quality of life by 12 weeks following intradiscal injection with durability sustained at the one-ye...

                          Brand Name : IDCT

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          October 11, 2022

                          Lead Product(s) : Allogeneic Discogenic Progenitor Cell Therapy

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : The Phase I/IIa study was a six-month open-label trial. It evaluated the safety and efficacy of ALLOB in the treatment of delayed-union fractures of long bones.

                          Brand Name : Allob

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          June 30, 2021

                          Lead Product(s) : Allogeneic Osteoblastic Cells

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : NVD-001 is Novadip’s first generation autologous cell-based osteogenic (bone healing) product derived from the Company’s proprietary tissue regeneration platform.

                          Brand Name : NVD-001

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          June 15, 2021

                          Lead Product(s) : NVD-001

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : This prospective, randomized, double-blinded, sham-controlled, multicenter clinical study is designed to evaluate the safety and preliminary efficacy of IDCT in patients with symptomatic, single-level, mild to moderate lumbar disc degeneration.

                          Brand Name : IDCT

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          April 27, 2021

                          Lead Product(s) : Rebonuputemcel

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank